What is Leerink Partnrs’ Estimate for LENZ FY2025 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Investment analysts at Leerink Partnrs cut their FY2025 earnings estimates for LENZ Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($2.65) for the year, down from their previous forecast of ($2.40). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ FY2026 earnings at ($2.70) EPS and FY2028 earnings at $1.35 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Trading Up 1.2 %

Shares of LENZ opened at $25.48 on Friday. The stock has a 50 day moving average price of $29.69 and a 200 day moving average price of $26.72. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period last year, the firm earned ($1.33) earnings per share.

Institutional Trading of LENZ Therapeutics

Several institutional investors have recently made changes to their positions in the company. Rhumbline Advisers grew its position in LENZ Therapeutics by 6.2% in the fourth quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock worth $541,000 after acquiring an additional 1,100 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of LENZ Therapeutics during the 4th quarter worth $29,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of LENZ Therapeutics during the 4th quarter worth about $168,000. SG Americas Securities LLC raised its holdings in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after buying an additional 935 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in LENZ Therapeutics in the 4th quarter valued at about $1,270,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.